PMC9950966_01
a Bronchial biopsy with metastasis of the salivary duct carcinoma: HE. b Nuclear androgen receptor immunoexpression (original magnification, x100).
cro-2023-0016-0001-529470_f1.jpg
PMC9950966_01_cro-2023-0016-0001-529470_f1.jpg
F1
In retrospect, it can be assumed that the tumor in 2013 was an SDC, which has now relapsed with multiple metastases, rather than acinic cell carcinoma, since it did not show expression of DOG1, SOX10, or amylase (Fig. 1a + b).
Thorax CT-scan axial/transversal before (09/2020, a) and after treatment (04/2021, b).
cro-2023-0016-0001-529470_f2.jpg
PMC9950966_01_cro-2023-0016-0001-529470_f2.jpg
F2
The CT scan of the lung 6 months after start of ADT showed a very good partial remission (PR) (Fig. 2a + b), and the MRI of the neurocranium showed a regression of the intracranial metastases (Fig. 3a + b).
Timeline of the main therapies and responses. P, progressive disease; PR, partial remission; SD, stable disease; Cis/Pem, chemotherapy with cisplatin and pemetrexed; ADT, androgen deprivation therapy.
cro-2023-0016-0001-529470_f4.jpg
PMC9950966_01_cro-2023-0016-0001-529470_f4.jpg
F4
ADT continues to show regression of the intracranial tumor manifestations. A timeline of the main therapies and responses is given in Figure 4.